( HongKong:2269 )

News from WuXi Biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 10, 2018, 18:54 ET WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


May 29, 2018, 20:34 ET WuXi Biologics and Tsinghua University Innovation Center for Immune Therapy Sign MOU and Announce Strategic Partnership

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


May 22, 2018, 06:34 ET WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


May 21, 2018, 08:30 ET WuXi Biologics and Bioasis Announce Initial Strategic Collaboration for the Development and Manufacturing of Bioasis' Lead Investigational Candidate to Treat Brain Cancer

Bioasis will draw on WuXi Biologics' expertise in developing complex biologic molecules for production of xB3-001 to support analytical...


May 16, 2018, 06:09 ET WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics...


Apr 30, 2018, 08:41 ET WuXi Biologics to Invest €325 Million to Build Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics...


Apr 16, 2018, 20:13 ET WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Mar 20, 2018, 20:18 ET WuXi Biologics to Install Industry's Largest Single-Use Bioreactor from ABEC at its New Commercial Manufacturing Facility

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Mar 19, 2018, 08:41 ET WuXi Biologics Reports Remarkable 2017 Annual Results: Revenue up 63.7% to a Record High of RMB1,618.8 Million

Revenue up 63.7% to a Record High of RMB1,618.8 Million Adjusted Net Profit up 85.1% to RMB408.1 Million Gross Profit Margin, Net Profit Margin and...


Mar 08, 2018, 22:43 ET WuXi Biologics and Adagene Announce Strategic Development and Manufacturing Partnership

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Mar 06, 2018, 23:24 ET WuXi Biologics Congratulates TaiMed on FDA Approval for Trogarzo

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Mar 06, 2018, 01:11 ET WuXi Biologics Receives Asia's CMO of 2017 from BioPharma Industry Awards

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Mar 05, 2018, 04:48 ET WuXi Biologics Announces Positive Profit Alert

WuXi Biologics (Stock Code: 2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for...


Feb 26, 2018, 19:04 ET WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Feb 08, 2018, 20:04 ET WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Jan 30, 2018, 18:52 ET WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Jan 29, 2018, 20:00 ET WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Jan 24, 2018, 04:05 ET WuXi Biologics Announces Formation of Scientific Advisory Board

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Jan 14, 2018, 19:10 ET WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer

WuXi Biologics (WuXi Bio, 02269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for...


Dec 14, 2017, 04:20 ET WuXi Biologics and Phanes Sign MOU and Announce Strategic Development and Manufacturing Partnership

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Dec 06, 2017, 03:23 ET WuXi Biologics Initiated cGMP Manufacturing in the World's Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics...


Nov 02, 2017, 22:30 ET WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory

WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Aug 22, 2017, 02:03 ET WuXi Biologics Announces 2017 Interim Results

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform...


Aug 17, 2017, 07:22 ET WuXi Biologics and Gloria Pharmaceuticals Announce the Licensure of the Fully Human PD-1 Antibody, GLS-010, to Arcus Biosciences

WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


Jun 12, 2017, 21:56 ET WuXi Biologics is Officially Listed on the Hong Kong Stock Exchange

On June 13, 2017 Hong Kong time, WuXi Biologics (Cayman) Inc. ("the Company"; stock code: 2269.HK) was officially listed during a grand listing...